To describe the pharmacology, pharmacokinetics, and clinical efficacy of mibefradil compared with other agents used for hypertension and angina.
DATA SOURCES:
A MEDLINE search was performed for the period of January 1980 through September 1997 using the key terms mibefradil or Ro 40–5967. All articles written in English were considered for review.
STUDY SELECTION AND DATA EXTRACTION:
All clinical studies involving mibefradil were evaluated. Preclinical data were included if these data were not adequately represented in clinical (human) studies.
DATA SYNTHESIS:
Mibefradil is the first member of a new class of calcium-channel antagonists (CCAs) that block the T-type calcium channels. A long elimination half-life makes once-daily dosing feasible, and the drug's lack of negative inotropy and reflex tachycardia distinguishes it from other available CCAs. When administered at recommended dosages (50 or 100 mg once daily), mibefradil reduces blood pressure over 24 hours in patients with hypertension, improves exercise capacity, and relieves anginal symptoms in patients with chronic stable angina pectoris.
CONCLUSIONS:
Clinical studies have found that the antihypertensive effects of mibefradil are comparable with those of nifedipine, verapamil, and amlodipine, and more effective than those of diltiazem. These effects result from peripheral vasodilation and a slight reduction in heart rate. Selective vasodilation of the coronary vasculature makes it an effective antianginal agent when used alone or added to β-blocker therapy. Mibefradil demonstrates no significant effects on cardiac contractility, and no adrenergic stimulation resulting in reflex tachycardia. Therefore, it may have some advantages over currently available CCAs, especially in patients with congestive heart failure, although such advantages are unproven in published clinical trials. Ongoing clinical studies, including the Mortality Assessment in Congestive Heart Failure Trial (MACH-1) currently in progress, are needed to clarify mibefradil's place in cardiovascular therapy.
OsterriederWHolckM. In vitro pharmacologic profile of Ro-40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol1989;13:754–9.
2.
ClozelJP. Pharmacology of the new calcium antagonist mibefradil. J Cardiovasc Pharmacol1996;27(suppl): S17–21.
3.
ClozelJPVeniantMOsterriederW. The structurally novel Ca2+ channel blocker Ro 40–5967, which binds to the [3H]-desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther1990;4:731–6.
4.
TriggleDJ. The classification of calcium antagonists. J Cardiovasc Pharmacol1996;27(suppl A): S11–6.
5.
RomeyGBoisPLazdunskiM. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805), on the L-type cardiac channel. Eur J Pharmacol1994;263:101–5.
6.
RutledgeATriggleDJ. The binding interactions of Ro 40–5967 at the L-type Ca2+ channel in cardiac tissue. Eur J Pharmacol1995;280:155–8.
7.
MishraSKHermsmeyerK. Selective inhibition of T-type Ca2+ channels by Ro 40–5967. Circ Res1994;75:144–8.
8.
FangLMOsterriederW. Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40–5967 and verapamil: Relation to negative inotropy. Eur J Pharmacol1991;196:205–7.
9.
BuhlerFRFleckenstein-GrunGClozelJPReidJLRousseauMFTriggleDJMibefradil, a new class of calcium antagonists: From molecular biology to clinical benefit. J Cardiovasc Pharmacol1996;27 (suppl):S1–3.
10.
ClozelJPBankenLOsterriederW. Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol1989;14:713–21.
11.
VeniantMClozelJPHessPWolfgangR. Ro 40–5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol1991;17:277–84.
12.
RousseauMFHayashidaWvan EyllCHessOMBenedictCRAhnSHemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol1996;28:972–9.
13.
PortegiesMCMSchmittRKraaijCJBraatSHJGGassnerAHagemeijerFLack of negative inotropic effects of the new calcium antagonist Ro 40–5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol1991;18:746–51.
14.
BianKHermsmeyerK. Ca2+ channel actions of the non-dihydropyri-dine Ca2+ channel antagonist Ro 40–5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Naunyn Schmiedebergs Arch Pharmacol1993;348:191–6.
15.
SchmittRKleinbloesemCHBelzGGSchroeterVFeifulUPozelHHemodynamic and humoral effects of the novel calcium antagonist Ro 40–5967 in patients with hypertension. Clin Pharmacol Ther1992;52:314–23.
16.
KatzAM. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol1996;28:522–9.
17.
NussHBHouserSR. T-type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res1993;73:777–82.
18.
ChapelleFStoleruLHayashidaWPouleurHHessOBenedictCRRo 40–5967, a new calcium antagonist profile: Bradycardia without myocardial depression (abstract)?Circulation1994;90(4 pt 2):I–28.
19.
HoeglundCWattAWilkinsMTenczerJCifkovaRMimranAThe effects of mibefradil on left ventricular hypertrophy with essential hypertension (abstract). Am J Hypertens1997;10(4 pt 2):124A.
20.
BillmanGE. Ro 40–5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol1992;229:179–87.
21.
WelkerHEggersHKleinbloesemCErbKBreithauptKButzerRRo 40–5967: Pharmacokinetics of a new calcium antagonist (abstract). Eur J Clin Pharmacol1989;36:A304.
22.
BerninkPJLMPragerGSchellingAKobrinI. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40–5967). Hypertension1996;27:426–32.
23.
OparilSKobrinIAbernethyDRLevineBSReifMCSheperdAM. Dose—response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens1997;10:735–42.
24.
ClozelJPOsterriederWKleinbloesemCHWelkerHASchlappiBTudorR. Ro 40–5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev1991;9:4–17.
AbernathyDR. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am J Cardiol1997;80(4B):4C–11C.
27.
PetrieJRGlenSKMacMahonMCromeRMeredithPAElliottHLHaemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40–5967), a novel calcium antagonist. J Hypertens1995;13:1842–6.
28.
LacourciereYPoirierLLefebvreJArchambaultFAveSJWardCThe antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens1997;10:189–96.
29.
BursztynMKadrHTilvisRMartinaBOlgmanWTalbergJMibefradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics. Am Heart J1997;134:238–47.
30.
CarneySWingLRibeiroAKallwellisRZimlichmanRViskoperRJThe addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens1997;11:459–66.
31.
SaseenJJCarterBLBrownTERElliottWJBlackHR. Comparison of nifedipine alone and with diltiazem or verapamil. Hypertension1996;28:109–14.
32.
CarterBLNoyesMADemmlerRW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy1993;13:359–68.
33.
MassieBMChrysantSGJainAWeirMWeissRKobrinI. Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clin Cardiol1997;20:562–8.
34.
ViskoperRJBerninkPJLMSchellingARibeiroABKantolaIMWilkinsMRA randomised, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens1997;11:459–66.
35.
RoseMMcMahonFG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens1990;3:151–5.
36.
BakxALMvan der WallEEBraunSEmanuelssonHBruschkeAVGKobrinI. On behalf of the Ro 40–5967 International Study Group. Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J1995;130:748–57.
37.
AlpertJSKobrinIDeQuattroVFriedmanRSheperdAFensterPEAdditional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Am J Cardiol1997;79:1025–30.
38.
TzivoniDKadrHBraatSRutschWRamiresJAKobrinI. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia; results of a multicenter, placebo-controlled trial. Circulation1997;96:2557–64.
39.
DaviesGJKobrinICaspiARelsinLHde AlbuquerqueD CamposArmagnijanDLong-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem. Am Heart J1997;134:220–8.
40.
KobrinICharlonVLindbergEPordyR. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Am J Cardiol1997;80(4 suppl B):40C–6C.
41.
HeldPHYusufSFurbergCD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview of the result from the randomized trials. Br Med J1989;299:1187–92.
42.
PsatyBMHeckbertSRKoepsellTDSiscovickDSRagunathanTEWeissNSThe risk of myocardial infarction associated with antihypertensive drug therapies. JAMA1995;274:620–5.
43.
FurbergCDPsatyBM. Calcium antagonists: Not appropriate as first line antihypertensive agents. Am J Hypertens1996;9:122–5.
44.
PahorMGuralnikJMFurbergCDCarboninPHavlikRJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet1996;347:1061–5.
45.
PahorMGuralnikJMFerrucciLCortiMCSaliveMECerhanJR. Calcium channel blockade and incidence of cancer in aged populations. Lancet1996;348:695–9.
46.
PahorMGuralnikJMSaliveMECortiMCCarboninPHavlikRJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens1996;9:695–9.
47.
EpsteinM. The calcium antagonist controversy: The emerging importance of drug formulation as a determinant of risk. Am J Cardiol1997;79(suppl 10A):9–19.
48.
PackerMO'ConnorCMGhaliJKPresslerMLCarsonPEBelkinRNEffect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med1996;335:1107–14.
49.
LevineTB. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol1997;20:320–6.
